Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

HealthEquity director Dilsaver sells over $2.5m in company stock

Published 03/28/2024, 03:32 PM
Updated 03/28/2024, 03:32 PM

HealthEquity, Inc. (NASDAQ:HQY) director Evelyn S. Dilsaver sold a substantial number of shares in the company, according to a recent SEC filing. On March 26, Dilsaver sold 32,500 shares of common stock at prices ranging from $78.86 to $79.73, netting a total of approximately $2.57 million.

The transactions were part of a series of sales and acquisitions involving HealthEquity stock. On the same day, Dilsaver also acquired 25,000 shares at $14.00 per share and another 7,500 shares at the same price, amounting to a total purchase value of $455,000. These acquisitions were related to stock options that were immediately exercisable as indicated in the footnotes of the filing.

Following the sales, Dilsaver's holdings in HealthEquity stock decreased, but she still owns a significant amount of shares. The SEC filing detailed that post-transaction, Dilsaver held 32,123 shares directly.

The recent transactions by Dilsaver come as investors closely monitor insider activity for insights into company performance and executive confidence. HealthEquity, a leader in providing health savings accounts and other health financial services, has seen its stock price fluctuate as the market adapts to changing economic conditions.

Investors and analysts often look at insider buying and selling as a signal of how executives perceive the company's future prospects. While the reasons behind Dilsaver's transactions were not disclosed, the substantial sale and corresponding acquisition of shares are noteworthy events for stakeholders.

HealthEquity has not issued any public statement regarding the transactions, and as per standard practice, the SEC filing serves as the formal record of the insider trading activity. The company's shares continue to be actively traded, and market watchers will undoubtedly keep an eye on any further developments involving insider transactions.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

For those interested in tracking the stock's performance and insider activities, HealthEquity's ticker symbol on the NASDAQ is HQY.

InvestingPro Insights

Amidst the recent insider trading activity at HealthEquity, Inc. (NASDAQ:HQY), investors are keen to understand the company's financial health and future prospects. An InvestingPro Tip indicates that analysts are expecting net income growth for HealthEquity this year, which could signal a positive outlook for the company's profitability. Moreover, the company is noted for trading at a low P/E ratio relative to near-term earnings growth, suggesting a potentially undervalued stock price in the eyes of some investors.

On the financial metrics front, HealthEquity boasts a market capitalization of $7.05 billion USD, reflecting its substantial presence in the health financial services sector. The company's P/E ratio stands at 126.04, with an adjusted P/E ratio for the last twelve months as of Q4 2024 at 110.91. This high earnings multiple may be a point of consideration for investors comparing the company's valuation to its peers. Additionally, HealthEquity has demonstrated strong revenue growth, with a 16.0% increase in the last twelve months as of Q4 2024, underlining its expanding operations.

For investors and analysts looking to delve deeper into HealthEquity's performance and insider trading patterns, further insights can be found on InvestingPro, which features a comprehensive analysis complete with additional InvestingPro Tips. There are 15 additional tips available for HealthEquity, which can provide a more nuanced view of the company's financial standing and market position. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.